Arcturus Therapeutics Holdings Inc. (ARCT) — SEC Filings
Arcturus Therapeutics Holdings Inc. (ARCT) — 41 SEC filings. Latest: 8-K (Dec 15, 2025). Includes 20 8-K, 8 SC 13G/A, 6 10-Q.
View Arcturus Therapeutics Holdings Inc. on SEC EDGAR
Overview
Arcturus Therapeutics Holdings Inc. (ARCT) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Dec 15, 2025: Arcturus Therapeutics Holdings Inc. filed an 8-K on December 15, 2025, reporting events as of December 11, 2025. The filing pertains to the departure of directors or certain officers, the election of directors, the appointment of certain officers, and compensatory arrangements for certain officers.
Sentiment Summary
Across 41 filings, the sentiment breakdown is: 2 bullish, 1 bearish, 38 neutral. The dominant filing sentiment for Arcturus Therapeutics Holdings Inc. is neutral.
Filing Type Overview
Arcturus Therapeutics Holdings Inc. (ARCT) has filed 20 8-K, 6 10-Q, 2 DEF 14A, 2 10-K, 2 SC 13G, 8 SC 13G/A, 1 8-K/A with the SEC between Jan 2024 to Dec 2025.
Filings by Year
Recent SEC Filings (41)
Risk Profile
Risk Assessment: Of ARCT's 30 recent filings, 1 were flagged as high-risk, 14 as medium-risk, and 15 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $74.835M |
| Net Income | -$36.704M |
| EPS | -$1.35 |
| Debt-to-Equity | 0.26 |
| Cash Position | $180.360M |
| Operating Margin | -59.9% |
| Total Assets | $282.343M |
| Total Debt | $57.784M |
Key Executives
- Dr. Steven Yi
- Dr. Charles L.SA. Wagner
Industry Context
Arcturus operates in the highly competitive and rapidly evolving gene therapy and mRNA therapeutics sector. This industry is characterized by substantial R&D investment, long development cycles, and significant regulatory hurdles. Key trends include the increasing focus on rare diseases and the potential for transformative treatments, but also the high cost of development and the need for strong intellectual property protection.
Top Tags
amendment (6) · institutional-ownership (6) · filing (5) · financial-condition (5) · results-of-operations (4) · corporate-governance (3) · Biotechnology (3) · Pharmaceuticals (3) · financials (3) · Clinical Trials (3)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Total Revenue (Q3 2025) | $17.151M | Decreased from $41.673M in Q3 2024 |
| Collaboration Revenue (Q3 2025) | $14.153M | Decreased from $38.815M in Q3 2024 |
| Net Loss (Q3 2025) | $13.448M | Increased from $6.903M in Q3 2024 |
| Total Revenue (YTD Sep 2025) | $74.835M | Decreased from $129.544M in YTD Sep 2024 |
| Net Loss (YTD Sep 2025) | $36.704M | Increased from $50.936M in YTD Sep 2024 |
| Research and Development Expenses (YTD Sep 2025) | $87.736M | Decreased from $151.376M in YTD Sep 2024 |
| Cash and Cash Equivalents (Sep 30, 2025) | $180.360M | Decreased from $237.028M at Dec 31, 2024 |
| Net Cash Used in Operating Activities (YTD Sep 2025) | $58.044M | Slightly decreased from $59.463M in YTD Sep 2024 |
| Shares Outstanding (Nov 5, 2025) | 28,412,537 | Total voting common stock outstanding |
| Collaboration Revenue | $104.9M | Increased from $17.2M in Q2 2024, primarily due to CSL agreement. |
| Net Income | $45.1M | Swung from a net loss of $50.3M in Q2 2024, indicating profitability. |
| R&D Expenses | $45.7M | Decreased from $55.1M in Q2 2024, mainly due to lower LUNAR-COVID costs. |
| Cash and Equivalents | $398.7M | Strong liquidity position as of June 30, 2025. |
| Reporting Period End Date | 2025-03-31 | Indicates the end of the fiscal quarter for which financial information is reported. |
| Previous Fiscal Year End | 2024-12-31 | Provides a point of comparison for retained earnings. |
Forward-Looking Statements
- {"claim":"Nikko Asset Management Americas, Inc. will maintain a passive investment strategy in Arcturus Therapeutics Holdings Inc.","entity":"Nikko Asset Management Americas, Inc.","targetDate":"Next 12 months","confidence":"high"}
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Arcturus Therapeutics Holdings Inc. (ARCT)?
Arcturus Therapeutics Holdings Inc. has 41 recent SEC filings from Jan 2024 to Dec 2025, including 20 8-K, 8 SC 13G/A, 6 10-Q. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of ARCT filings?
Across 41 filings, the sentiment breakdown is: 2 bullish, 1 bearish, 38 neutral. The dominant sentiment is neutral.
Where can I find Arcturus Therapeutics Holdings Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Arcturus Therapeutics Holdings Inc. (ARCT) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Arcturus Therapeutics Holdings Inc.?
Key financial highlights from Arcturus Therapeutics Holdings Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for ARCT?
The investment thesis for ARCT includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Arcturus Therapeutics Holdings Inc.?
Key executives identified across Arcturus Therapeutics Holdings Inc.'s filings include Dr. Steven Yi, Dr. Charles L.SA. Wagner.
What are the main risk factors for Arcturus Therapeutics Holdings Inc. stock?
Of ARCT's 30 assessed filings, 1 were flagged high-risk, 14 medium-risk, and 15 low-risk.
What are recent predictions and forward guidance from Arcturus Therapeutics Holdings Inc.?
Recent forward-looking statements from Arcturus Therapeutics Holdings Inc. include guidance on {"claim":"Nikko Asset Management Americas, Inc. will maintain a passive investment strategy in Arcturus Therapeutics Hol.